Neoadjuvant study group patients had an even longer disease-free interval (35 months versus 6 months) and higher disease-free survival (81% versus 40%) (Figure 4(b); p < 0.0001) in the presence of elevated Gal-3 in tumor stroma. This evidence concerns the gene LGALS3 and neoplasm.